483
Boehringer Ingelheim Pharmaceuticals, Inc.FDA 483 - Boehringer Ingelheim Pharmaceuticals, Inc. - September 11, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield, CT, identified a significant issue regarding their clinical trial sponsor responsibilities. The firm failed to adhere to its Trial Statistical Analysis Plan by not excluding data associated with important protocol deviations from supplementary analyses. This oversight may compromise the integrity and reliability of the clinical trial data and results.
Open in Dashboard
ID · 6394b726-4080-4f87-8203-78db8a187c7a